Clinical research
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
The company indicated it is shutting down its gosuranemab program for PSP and other primary tauopathies.
New findings from the Phase III KEYNOTE-042 Study show improvements in overall survival, progression-free survival and overall response rate in patients treated with Keytruda as a monotherapy.
AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens.
Companies from across the globe provide updates to their business and pipelines.
It missed the primary endpoint by a narrow margin—so narrow, in fact, it comes to about a single patient.
Sanofi believes that sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious and chronic rare blood disorder.
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients
BioSpace put together a list of the top 10 indications being researched in the area by pharma companies, academic institutions and other organizations.
Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.
PRESS RELEASES